{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:15:10Z","timestamp":1789578910835,"version":"build-2803163510"},"reference-count":45,"publisher":"Elsevier BV","issue":"11","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007343","name":"Shire","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007343","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007723","name":"Takeda Pharmaceuticals U.S.A.","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007723","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100030825","name":"Ascendis Pharma Denmark","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100030825","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["aacejournalendocrinepractice.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Endocrine Practice"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.eprac.2025.07.009","type":"journal-article","created":{"date-parts":[[2025,7,17]],"date-time":"2025-07-17T23:11:15Z","timestamp":1752793875000},"page":"1488-1494","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"title":["Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives"],"prefix":"10.1016","volume":"31","author":[{"given":"Sheryl T.Y.","family":"Htoo","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-5336","authenticated-orcid":false,"given":"Natalie E.","family":"Cusano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.eprac.2025.07.009_bib1","doi-asserted-by":"crossref","first-page":"e868","DOI":"10.1210\/clinem\/dgae659","article-title":"Approach to the patient: normocalcemic primary hyperparathyroidism","volume":"110","author":"Liu","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.009_bib2","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1002\/jbmr.4677","article-title":"International Workshop on primary hyperparathyroidism. Evaluation and management of primary hyperparathyroidism: summary statement and guidelines from the Fifth international Workshop","volume":"37","author":"Bilezikian","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.009_bib3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.bone.2014.12.003","article-title":"Secular trends in the incidence of primary hyperparathyroidism over five decades (1965-2010)","volume":"73","author":"Griebeler","year":"2015","journal-title":"Bone"},{"key":"10.1016\/j.eprac.2025.07.009_bib4","doi-asserted-by":"crossref","first-page":"2315","DOI":"10.1002\/jbmr.4665","article-title":"Epidemiology, pathophysiology, and genetics of primary hyperparathyroidism","volume":"37","author":"Minisola","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.009_bib5","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1210\/jc.2012-4022","article-title":"Incidence and prevalence of primary hyperparathyroidism in a racially mixed population","volume":"98","author":"Yeh","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.009_bib6","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0230130","article-title":"Epidemiology and management of parathyroid gland disorders in Spain over 15 years: a retrospective multicentre analysis","volume":"15","author":"Darb\u00e0","year":"2020","journal-title":"PLoS One"},{"key":"10.1016\/j.eprac.2025.07.009_bib7","article-title":"Increasing incidence of primary hyperparathyroidism in Denmark","volume":"60","author":"Abood","year":"2013","journal-title":"Dan Med J"},{"key":"10.1016\/j.eprac.2025.07.009_bib8","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1590\/S0100-879X2005000900013","article-title":"Changes in clinical and laboratory findings at the time of diagnosis of primary hyperparathyroidism in a University Hospital in S\u00e3o Paulo from 1985 to 2002","volume":"38","author":"Ohe","year":"2005","journal-title":"Braz J Med Biol Res"},{"key":"10.1016\/j.eprac.2025.07.009_bib9","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1007\/s00198-017-4322-7","article-title":"Characteristics, management, and outcome of primary hyperparathyroidism at a single clinical center from 2005 to 2016","volume":"29","author":"Sun","year":"2018","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.eprac.2025.07.009_bib10","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1055\/a-0859-1020","article-title":"Normocalcemic primary hyperparathyroidism in adults without a history of nephrolithiasis or fractures: a prospective study","volume":"51","author":"Ros\u00e1rio","year":"2019","journal-title":"Horm Metab Res"},{"key":"10.1016\/j.eprac.2025.07.009_bib11","doi-asserted-by":"crossref","first-page":"3570","DOI":"10.1210\/jc.2014-1414","article-title":"Diagnosis of asymptomatic primary hyperparathyroidism: proceedings of the Fourth International Workshop","volume":"99","author":"Eastell","year":"2014","journal-title":"J Clin Endocrinol Metab"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.009_bib12","doi-asserted-by":"crossref","first-page":"1364","DOI":"10.1093\/clinchem\/33.8.1364","article-title":"Highly sensitive two-site immunoradiometric assay of parathyrin, and its clinical utility in evaluating patients with hypercalcemia","volume":"33","author":"Nussbaum","year":"1987","journal-title":"Clin Chem"},{"key":"10.1016\/j.eprac.2025.07.009_bib13","doi-asserted-by":"crossref","first-page":"3138","DOI":"10.1210\/jc.2012-1429","article-title":"The importance of measuring ionized calcium in characterizing calcium status and diagnosing primary hyperparathyroidism","volume":"97","author":"Ong","year":"2012","journal-title":"J Clin Endocrinol Metab"},{"issue":"16","key":"10.1016\/j.eprac.2025.07.009_bib14","doi-asserted-by":"crossref","first-page":"1624","DOI":"10.1001\/jama.2022.18331","article-title":"Hypercalcemia: a review","volume":"328","author":"Walker","year":"2022","journal-title":"JAMA"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.009_bib15","doi-asserted-by":"crossref","first-page":"451","DOI":"10.4158\/EP12158.OR","article-title":"Falsely low parathyroid hormone secondary to biotin interference: a case series","volume":"19","author":"Waghray","year":"2013","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.009_bib16","doi-asserted-by":"crossref","first-page":"666","DOI":"10.20945\/2359-3997000000556","article-title":"Normocalcemic primary hyperparathyroidism","volume":"66","author":"Cusano","year":"2022","journal-title":"Arch Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.009_bib17","doi-asserted-by":"crossref","first-page":"R33","DOI":"10.1530\/EJE-21-1044","article-title":"European expert consensus on practical management of specific aspects of parathyroid disorders in adults and in pregnancy: recommendations of the ESE Educational Program of Parathyroid Disorders (PARAT 2021)","volume":"186","author":"Bollerslev","year":"2021","journal-title":"Eur J Endocrinol"},{"issue":"8","key":"10.1016\/j.eprac.2025.07.009_bib18","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.99123","article-title":"Canagliflozin triggers the FGF23\/1,25-dihydroxyvitamin D\/PTH axis in healthy volunteers in a randomized crossover study","volume":"3","author":"Blau","year":"2018","journal-title":"JCI Insight"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.009_bib19","doi-asserted-by":"crossref","first-page":"1069","DOI":"10.1016\/j.eprac.2022.07.009","article-title":"Calcium challenge to confirm secondary hyperparathyroidism caused by decreased calcium intake","volume":"28","author":"Shokry","year":"2022","journal-title":"Endocr Pract"},{"key":"10.1016\/j.eprac.2025.07.009_bib20","doi-asserted-by":"crossref","first-page":"3443","DOI":"10.1210\/jc.2015-2022","article-title":"Vitamin D in primary hyperparathyroidism: effects on clinical, biochemical, and densitometric presentation","volume":"100","author":"Walker","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.009_bib21","doi-asserted-by":"crossref","first-page":"380","DOI":"10.1007\/s12020-017-1414-2","article-title":"Osteitis fibrosa cystica-a forgotten radiological feature of primary hyperparathyroidism","volume":"58","author":"Misiorowski","year":"2017","journal-title":"Endocrine"},{"key":"10.1016\/j.eprac.2025.07.009_bib22","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1056\/NEJM196605262742105","article-title":"The story of hyperparathyroidism at the Massachusetts General Hospital","volume":"274","author":"Cope","year":"1966","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.009_bib23","doi-asserted-by":"crossref","DOI":"10.1016\/j.beem.2025.101980","article-title":"Changing trends in clinical presentation of primary hyperparathyroidism across countries over time","volume":"39","author":"Arjunan","year":"2025","journal-title":"Best Pract Res Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.009_bib24","doi-asserted-by":"crossref","first-page":"1309","DOI":"10.1210\/jc.2014-3708","article-title":"Prevalence of kidney stones and vertebral fractures in primary hyperparathyroidism using imaging technology","volume":"100","author":"Cipriani","year":"2015","journal-title":"J Clin Endocrinol Metab"},{"issue":"2","key":"10.1016\/j.eprac.2025.07.009_bib25","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1080\/07435800.2018.1431275","article-title":"Occult urolithiasis in asymptomatic primary hyperparathyroidism","volume":"43","author":"Tay","year":"2018","journal-title":"Endocr Res"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.009_bib26","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s42000-023-00508-9","article-title":"Genetics of hereditary forms of primary hyperparathyroidism","volume":"23","author":"English","year":"2024","journal-title":"Hormones (Athens)"},{"key":"10.1016\/j.eprac.2025.07.009_bib27","doi-asserted-by":"crossref","first-page":"1396","DOI":"10.1056\/NEJMc1511646","article-title":"Cinacalcet for symptomatic hypercalcemia caused by AP2S1 mutations","volume":"374","author":"Howles","year":"2016","journal-title":"N Engl J Med"},{"key":"10.1016\/j.eprac.2025.07.009_bib28","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1016\/j.surg.2006.07.032","article-title":"Cost-effectiveness analysis of parathyroidectomy for asymptomatic primary hyperparathyroidism","volume":"140","author":"Zanocco","year":"2006","journal-title":"Surgery"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.009_bib29","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1001\/jamaoto.2018.1671","article-title":"Preoperative imaging techniques in primary hyperparathyroidism: a review","volume":"144","author":"Bunch","year":"2018","journal-title":"JAMA Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.eprac.2025.07.009_bib30","doi-asserted-by":"crossref","DOI":"10.1016\/j.suronc.2021.101550","article-title":"Thyroid and parathyroid surgeon case volume influences patient outcomes: a systematic review","volume":"38","author":"Bedi","year":"2021","journal-title":"Surg Oncol"},{"issue":"10","key":"10.1016\/j.eprac.2025.07.009_bib31","doi-asserted-by":"crossref","first-page":"959","DOI":"10.1001\/jamasurg.2016.2310","article-title":"The American association of endocrine surgeons guidelines for definitive management of primary hyperparathyroidism","volume":"151","author":"Wilhelm","year":"2016","journal-title":"JAMA Surg"},{"key":"10.1016\/j.eprac.2025.07.009_bib32","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1177\/0194599818793879","article-title":"Surgical management of normocalcemic primary hyperparathyroidism and the impact of intraoperative parathyroid hormone testing on outcome","volume":"159","author":"Trinh","year":"2018","journal-title":"Otolaryngol Head Neck Surg"},{"key":"10.1016\/j.eprac.2025.07.009_bib33","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1001\/archsurg.2010.108","article-title":"Are additional localization studies and referral indicated for patients with primary hyperparathyroidism who have negative sestamibi scan results?","volume":"145","author":"Elaraj","year":"2010","journal-title":"Arch Surg"},{"key":"10.1016\/j.eprac.2025.07.009_bib34","doi-asserted-by":"crossref","first-page":"3213","DOI":"10.1210\/jc.2013-1518","article-title":"Bone mineral density evolution after successful parathyroidectomy in patients with normocalcemic primary hyperparathyroidism","volume":"98","author":"Koumakis","year":"2013","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.009_bib35","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1530\/EJE-14-0355","article-title":"The PRIMARA study: a prospective, descriptive, observational study to review cinacalcet use in patients with primary hyperparathyroidism in clinical practice","volume":"171","author":"Schwarz","year":"2014","journal-title":"Eur J Endocrinol"},{"key":"10.1016\/j.eprac.2025.07.009_bib36","doi-asserted-by":"crossref","first-page":"2351","DOI":"10.1002\/jbmr.4685","article-title":"The efficacy and safety of medical and surgical therapy in patients with primary hyperparathyroidism: a systematic review and meta-analysis of randomized controlled trials","volume":"37","author":"Ye","year":"2022","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.eprac.2025.07.009_bib37","doi-asserted-by":"crossref","first-page":"3319","DOI":"10.1210\/jc.2003-030908","article-title":"Alendronate in primary hyperparathyroidism: a double-blind, randomized, placebo-controlled trial","volume":"89","author":"Khan","year":"2004","journal-title":"J Clin Endocrinol Metab"},{"issue":"11","key":"10.1016\/j.eprac.2025.07.009_bib38","doi-asserted-by":"crossref","first-page":"715","DOI":"10.7326\/M15-1232","article-title":"The relationship of parathyroidectomy and bisphosphonates with fracture risk in primary hyperparathyroidism: an observational study","volume":"164","author":"Yeh","year":"2016","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.eprac.2025.07.009_bib39","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1016\/S2213-8587(20)30063-2","article-title":"Denosumab and cinacalcet for primary hyperparathyroidism (DENOCINA): a randomised, double-blind, placebo-controlled, phase 3 trial","volume":"8","author":"Leere","year":"2020","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.eprac.2025.07.009_bib40","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1530\/EC-20-0380","article-title":"Denosumab for management of severe hypercalcemia in primary hyperparathyroidism","volume":"9","author":"Eremkina","year":"2020","journal-title":"Endocr Connect"},{"key":"10.1016\/j.eprac.2025.07.009_bib41","doi-asserted-by":"crossref","DOI":"10.1210\/clinem\/dgaf107","article-title":"The efficacy and safety of denosumab for treating hypercalcemia in primary hyperparathyroidism: a retrospective study","author":"Song","year":"2025","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.eprac.2025.07.009_bib42","doi-asserted-by":"crossref","first-page":"2161","DOI":"10.1001\/archinte.160.14.2161","article-title":"Effects of hormone replacement therapy on bone mineral density in postmenopausal women with primary hyperparathyroidism: four-year follow-up and comparison with healthy postmenopausal women","volume":"160","author":"Orr-Walker","year":"2000","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.eprac.2025.07.009_bib43","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1210\/jc.2002-020667","article-title":"Raloxifene lowers serum calcium and markers of bone turnover in postmenopausal women with primary hyperparathyroidism","volume":"88","author":"Rubin","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"issue":"1","key":"10.1016\/j.eprac.2025.07.009_bib44","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1359\/jbmr.2001.16.1.189","article-title":"Raloxifene reverses bone loss in postmenopausal women with mild asymptomatic primary hyperparathyroidism","volume":"16","author":"Zanchetta","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.1016\/j.eprac.2025.07.009_bib45","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1007\/s12020-011-9459-0","article-title":"Cinacalcet hydrochloride in combination with alendronate normalizes hypercalcemia and improves bone mineral density in patients with primary hyperparathyroidism","volume":"39","author":"Faggiano","year":"2011","journal-title":"Endocrine"}],"container-title":["Endocrine Practice"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2500967X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1530891X2500967X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,5]],"date-time":"2026-03-05T21:33:49Z","timestamp":1772746429000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1530891X2500967X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":45,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S1530891X2500967X"],"URL":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.009","relation":{},"ISSN":["1530-891X"],"issn-type":[{"value":"1530-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Management of Primary Hyperparathyroidism: Historical and Contemporary Perspectives","name":"articletitle","label":"Article Title"},{"value":"Endocrine Practice","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.eprac.2025.07.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 AACE. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}